Arecor Therapeutics plc
AREC.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £5,053 | £4,573 | £2,403 | £1,158 |
| % Growth | 10.5% | 90.3% | 107.5% | – |
| Cost of Goods Sold | £3,510 | £3,322 | £341 | £0 |
| Gross Profit | £1,543 | £4,573 | £2,403 | £1,158 |
| % Margin | 30.5% | 100% | 100% | 100% |
| R&D Expenses | £3,041 | £5,977 | £8,613 | £5,386 |
| G&A Expenses | £6,178 | £8,913 | £5,552 | £2,389 |
| SG&A Expenses | £6,178 | £8,913 | £5,552 | £2,389 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £3,021 | -£1,142 | -£1,250 | -£640 |
| Operating Expenses | £12,240 | £13,748 | £12,915 | £7,135 |
| Operating Income | -£10,697 | -£9,175 | -£11,660 | -£5,977 |
| % Margin | -211.7% | -200.6% | -485.2% | -516.1% |
| Other Income/Exp. Net | £79 | £274 | £88 | -£506 |
| Pre-Tax Income | -£10,618 | -£8,901 | -£10,542 | -£6,945 |
| Tax Expense | -£382 | -£347 | -£1,282 | -£776 |
| Net Income | -£10,236 | -£8,554 | -£9,260 | -£6,169 |
| % Margin | -202.6% | -187.1% | -385.4% | -532.7% |
| EPS | -0.31 | -0.28 | -0.32 | -0.27 |
| % Growth | -10.7% | 12.5% | -18.5% | – |
| EPS Diluted | -0.31 | -0.28 | -0.32 | -0.27 |
| Weighted Avg Shares Out | 33,440 | 30,623 | 28,936 | 23,033 |
| Weighted Avg Shares Out Dil | 33,440 | 30,623 | 28,936 | 23,033 |
| Supplemental Information | – | – | – | – |
| Interest Income | £101 | £284 | £109 | £1 |
| Interest Expense | £22 | £15 | £21 | £507 |
| Depreciation & Amortization | £446 | £496 | £341 | £171 |
| EBITDA | -£10,150 | -£8,390 | -£10,062 | -£6,267 |
| % Margin | -200.9% | -183.5% | -418.7% | -541.2% |